320 related articles for article (PubMed ID: 33706022)
1. Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
Moreno-Ruiz P; Corvigno S; Te Grootenhuis NC; La Fleur L; Backman M; Strell C; Mezheyeuski A; Hoelzlwimmer G; Klein C; Botling J; Micke P; Östman A
Lung Cancer; 2021 May; 155():10-19. PubMed ID: 33706022
[TBL] [Abstract][Full Text] [Related]
2. Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Kilvaer TK; Khanehkenari MR; Hellevik T; Al-Saad S; Paulsen EE; Bremnes RM; Busund LT; Donnem T; Martinez IZ
PLoS One; 2015; 10(8):e0134965. PubMed ID: 26252379
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis.
Liao Y; Ni Y; He R; Liu W; Du J
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1523-8. PubMed ID: 23835897
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
Mathieson L; Koppensteiner L; Dorward DA; O'Connor RA; Akram AR
Br J Cancer; 2024 May; 130(11):1758-1769. PubMed ID: 38582812
[TBL] [Abstract][Full Text] [Related]
5. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
6. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.
Zhao Y; Liu Y; Jia Y; Wang X; He J; Zhen S; Wang J; Liu L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3469-3483. PubMed ID: 35951090
[TBL] [Abstract][Full Text] [Related]
8. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen.
Ogawa Y; Masugi Y; Abe T; Yamazaki K; Ueno A; Fujii-Nishimura Y; Hori S; Yagi H; Abe Y; Kitago M; Sakamoto M
Clin Cancer Res; 2021 Jan; 27(1):107-119. PubMed ID: 33046515
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.
Pellinen T; Paavolainen L; Martín-Bernabé A; Papatella Araujo R; Strell C; Mezheyeuski A; Backman M; La Fleur L; Brück O; Sjölund J; Holmberg E; Välimäki K; Brunnström H; Botling J; Moreno-Ruiz P; Kallioniemi O; Micke P; Östman A
J Natl Cancer Inst; 2023 Jan; 115(1):71-82. PubMed ID: 36083003
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
Wang M; Li P; Wan R; Liu X
Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
[TBL] [Abstract][Full Text] [Related]
14. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
[TBL] [Abstract][Full Text] [Related]
15. High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma.
Yanagawa N; Sugai M; Shikanai S; Sugimoto R; Osakabe M; Uesugi N; Saito H; Maemondo M; Sugai T
Thorac Cancer; 2022 Aug; 13(16):2377-2384. PubMed ID: 35818720
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
17. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
19. Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC.
Koeck S; Amann A; Kern J; Zwierzina M; Lorenz E; Sopper S; Zwierzina H; Mildner F; Sykora M; Sprung S; Hackl H; Augustin F; Maier HT; Pircher A; Pall G; Wolf D; Gamerith G
Oncoimmunology; 2023; 12(1):2274130. PubMed ID: 38126028
[TBL] [Abstract][Full Text] [Related]
20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
